Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran; Department of Medical Nanotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
Department of Medical Nanotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran; Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Biomed Pharmacother. 2020 Dec;132:110850. doi: 10.1016/j.biopha.2020.110850. Epub 2020 Oct 14.
Cancer is the second most extended disease with an improved death rate over the past several time. Due to the restrictions of cancer analysis methods, the patient's real survival rate is unknown. Therefore, early stage diagnosis of cancer is crucial for its strong detection. Bio-analysis based on biomarkers may help to overcome the problem Biosensors with high sensitivity and specificity, low-cost, high analysis speed and minimum limit of detection are practical alternatives for laboratory tests. Surface plasmon resonance (SPR) is reaching a maturity level sufficient for their application in detection and determination cancer biomarkers in clinical samples. This review discusses main concepts and performance characteristics of SPR biosensor. Mainly, it focuses on newly emerged enhanced SPR biosensors towards high-throughput and ultrasensitive screening of cancer biomarkers such as PSA, α-fetoprotein, CEA, CA125, CA 15-3, HER2, ctDNA, ALCAM, hCG, VEGF, TNF, Interleukin, IFN-γ, CD24, CD44, Ferritin, COLIV using labeling processes with focusing on the future application in biomedical research and clinical diagnosis. This article reviews current status of the field, showcasing a series of early successes in the application of SPR for clinical bioanalysis of cancer related biomolecules and detailing a series of considerations regarding sensing schemes, exposing issues with analysis in biofluids, while providing an outlook of the challenges currently associated with plasmonic materials, bioreceptor selection, microfluidics, and validation of a clinical bioassay for applying SPR biosensors to clinical samples. Research opportunities are proposed to further advance the field and transition SPR biosensors from research proof-of-concept stage to actual clinical usage.
癌症是第二大常见疾病，其死亡率在过去几年中有所提高。由于癌症分析方法的限制，患者的真实存活率未知。因此，癌症的早期诊断对于其早期发现至关重要。基于生物标志物的生物分析可能有助于克服这个问题。具有高灵敏度和特异性、低成本、高分析速度和最小检测限的生物传感器是实验室测试的实用替代品。表面等离子体共振 (SPR) 技术已经达到了足够成熟的水平，可用于检测和确定临床样本中的癌症生物标志物。本文综述了 SPR 生物传感器的主要概念和性能特点。主要集中在新兴的增强 SPR 生物传感器上，用于高通量和超灵敏筛选 PSA、α-胎蛋白、CEA、CA125、CA 15-3、HER2、ctDNA、ALCAM、hCG、VEGF、TNF、白细胞介素、IFN-γ、CD24、CD44、铁蛋白、COLIV 等癌症生物标志物，重点介绍了使用标记过程的最新进展，关注其在生物医学研究和临床诊断中的未来应用。本文综述了该领域的现状，展示了 SPR 在癌症相关生物分子的临床生物分析中的一系列早期成功应用，并详细讨论了传感方案的一系列考虑因素，揭示了生物流体分析中的问题，同时展望了与等离子体材料、生物受体选择、微流控和临床生物分析验证相关的挑战，将 SPR 生物传感器应用于临床样本。提出了研究机会，以进一步推动该领域的发展，并将 SPR 生物传感器从研究概念验证阶段过渡到实际的临床应用。
